-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Verve Therapeutics, Inc. quarterly Deferred Income Tax Expense (Benefit) history and growth rate from 2020 to 2023.
- Verve Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending December 31, 2023 was $0.000.
- Verve Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the twelve months ending December 31, 2023 was $0.000.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Quarterly Data (USD)